The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01012570 |
Recruitment Status
:
Terminated
(not enough patients enrolled)
First Posted
: November 13, 2009
Last Update Posted
: December 4, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The investigators will study the effect of Adalimumab on the bone microstructure.
- Trial with medicinal product
Condition or disease | Intervention/treatment |
---|---|
Crohn's Disease | Drug: Application of Adalimumab |
Study Type : | Observational |
Actual Enrollment : | 34 participants |
Observational Model: | Case Control |
Time Perspective: | Prospective |
Study Start Date : | August 2009 |
Actual Primary Completion Date : | August 2011 |

-
Drug: Application of Adalimumab

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion criteria:
- CDAI > 220 und < 450
- Biologika naiv
- CD seit > 6 Monaten
Exclusion criteria:
- other TNF-Blocker
- Steroids > 40 mg
- Malignoma in der Anamnesis

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01012570
Switzerland | |
Zurich, Switzerland |
Study Director: | 01 Studienregister MasterAdmins | UniversitaetsSpital Zuerich |
Responsible Party: | Gerhard Rogler, Prof.Dr.Dr. gerhard Rogler, University of Zurich |
ClinicalTrials.gov Identifier: | NCT01012570 History of Changes |
Other Study ID Numbers: |
HUM-07-019 |
First Posted: | November 13, 2009 Key Record Dates |
Last Update Posted: | December 4, 2014 |
Last Verified: | December 2014 |
Additional relevant MeSH terms:
Crohn Disease Inflammatory Bowel Diseases Gastroenteritis Gastrointestinal Diseases Digestive System Diseases |
Intestinal Diseases Adalimumab Anti-Inflammatory Agents Antirheumatic Agents |